Leukemia

Risk of Relapse Up for Young Adults With Leukemia

Risk of Relapse Up for Young Adults With Leukemia

Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia

Lumoxiti, a CD22-directed cytotoxin, has been approved for adult patients who have had at least two prior therapies for the disease.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

By

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

By

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

Ibrutinib Compared With Chemotherapy in Treatment-Naive CLL

By

Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

Bendamustine Plus Obinutuzumab, Venetoclax Shows Therapeutic Potential in CLL

By

Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

By

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

By

A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

By

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Lorazepam Did Not Improve CINV in Pediatric Acute Lymphoblastic Leukemia

Lorazepam Did Not Improve CINV in Pediatric Acute Lymphoblastic Leukemia

By

A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.

De-Escalation or Stoppage May Be Effective After Response to TKI Therapy in CML

De-Escalation or Stoppage May Be Effective After Response to TKI Therapy in CML

De-escalation of TKI therapy may be an effective management strategy among patients with CML who have responded to therapy.

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

Remission Duration Predicts Long-Term Outcomes in Chronic Lymphocytic Leukemia

By

A retrospective study sought to evaluate outcomes for patients with CLL who were treated with FCR, a highly effective treatment, and initially had refractory disease, experienced relapse early, or were unable to complete therapy due to toxicity.

Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events

Low-Dose Dasatinib for Chronic-Phase CML Safe, Effective With Fewer Adverse Events

By

In this study, researchers assigned 75 patients with newly diagnosed Philadelphia chromosome (Ph)-positive CML-CP to receive dasatinib 50 mg once daily.

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

By

In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

By

FDA approval was based on results of the single-arm phase 2 JULIET clinical trial.

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

By

An assessment of more than 71,000 patients with leukemia demonstrated the difference in outcomes for patients admitted to hospital on the weekend vs weekday. Findings were presented at the 2018 ASCO Annual Meeting.

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

By

Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

By

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

By

Teaming up with multiple specialists to create an algorithm for managing AML in older patients improved clinician knowledge as well as provided patient-centered care, a presentation at 2018 ONS Annual Congress has shown.

Symptoms, Quality of Life May Improve During Hospitalization for Acute Leukemia

Symptoms, Quality of Life May Improve During Hospitalization for Acute Leukemia

By

Results of a prospective, longitudinal study presented at 2018 ONS Congress demonstrate improvement from baseline to discharge patients with acute leukemia who receive induction chemotherapy in hospital.

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

By

Accelerated approval was granted by the FDA based on the results of a single-arm trial.

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

By

A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

By

Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

By

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

By

Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

By

This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

By

The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs